Elmedix raises €4 million for clinical tests of cancer therapy
The Leuven-based medical tech company ElmediX has succeeded in raising €4 million to finance testing of a process which would allow cancer patients to be heat-treated in preparation for treatment for chemo- and radio-therapy.
Elmedix has developed a technology which allows it to bring the temperature of cancer patients up to 41.5 degrees Celsius and maintain it at that level for a few hours.
The result of the so-called thermic therapy is that tumour cells are killed off, while healthy cells remain unaffected. At the same time, the susceptibility of the cancer cells to chemo- and radio-therapy is increased, boosting the immune system of the patient.
The secret of the therapy is that it not only kills off cancer cells directly, but also spares healthy cells, as well as boosting the immune system of the patient, which fights its own fight against the cancer.
“Our technology makes warm air circulate in the machine to warm the body up temporarily, while sensors in the patient monitor the patient to make sure things don’t become too warm,” explained ElmediX CEO Jean-Paul Bogers. “Research has shown that the best effects come from a precise temperature of 41.5 degrees Centigrade.” The normal body temperature of a healthy human being is around 37 degrees Celsius.
The therapy is for the time being not yet approved for use other than in the experimental phase. Some very localised therapies are approved, but not one to the extent of the ElmediX therapy, despite testing going back to 2020. One reason for the delay: testing had to be paused as a result of the Covid-19 pandemic.
“The results in the first patients are promising,” said Professor John-Paul Bogers, CEO of ElmediX. “The confidence of our investors and the additional capital injection allow us to expand the first clinical trial and treat more patients. We are also developing a biomarker that can indicate in advance which patients and cancers have more chance of success."
Source: Brussels Times
In 2020, Elmedix was also covered in the news with the same technology because of the possible impact of this innovation to fight the corona virus. It was a collaboration between two Leuven MindGate members: RAAK and Elmedix.
Related News
ArtiQ joins forces with Clario in strategic acquisition deal to transform respiratory solutions
Leuven models help unlock the dark part of space in the largest European Space Agency mission ever
QbD Chair for Precision Oncology Research in Glioblastoma extended for three years
Zeopore is making its mark in emerging green applications through catalyst optimization leadership
Leuven-based hydrogen panels become an official KU Leuven spin-off
Leuven's imec research centre targets 1950 new hires by 2035
Materialise plays crucial role in world's first-ever eye transplant
KU Leuven students win the world championships for solar cars!
Leuven-based VirusBank Platform enhances society's preparedness against future viral epidemics and pandemics
Leuven's Centre for Drug Design and Discovery (CD3) raises € 70.5 Million
International School in Leuven opens new school building for children of expats
Qaelum NV Partners with I-MED Radiology Network to Enhance Patient Dose Analysis and Incident Reporting in the ANZ Region
How can we help?
The Leuven MindGate team is at your disposal for any questions about the Leuven Innovation Region. Do you want to invest, work or study in the region? We can help you find your way.
We also facilitate collaboration and innovation between companies, knowledge institutes and government within the Leuven Innovation Region, and we are happy to guide any of these stakeholders towards innovation.